Metsera, A Wholly Owned Subsidiary Of Pfizer
Clinical trials sponsored by Metsera, A Wholly Owned Subsidiary Of Pfizer, explained in plain language.
-
New weekly shot shows promise for weight loss in early trial
Disease control CompletedThis study tested a new medicine called MET097, given as a weekly injection, to see if it is safe and helps with weight loss in adults who are overweight or have obesity but are otherwise healthy. About 120 people took part, receiving either the drug or a placebo for up to 12 wee…
Phase: PHASE1, PHASE2 • Sponsor: Metsera, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 26, 2026 08:01 UTC
-
New weekly shot shows promise for weight loss and diabetes control
Disease control CompletedThis study tested a new once-weekly injection called MET097 in 133 adults who are overweight or have obesity and also have type 2 diabetes. The goal was to see if it helps with weight loss and improves blood sugar levels compared to a placebo over 28 weeks. Participants received …
Phase: PHASE2 • Sponsor: Metsera, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 04, 2026 16:18 UTC